Objective: To examine whether a plausible estimate of the prevalence of schizophrenia can be obtained with a self-report item in a health survey.
Methods: We estimated a self-reported prevalence of schizophrenia, using a grouped variable for all people who reported schizophrenia or any other psychotic disorder in the Canadian Community Health Survey: Mental Health and Well-Being (n = 36,984). Estimates were stratified according to age, sex, and province of residence.
Results: Of survey respondents, 411 (1.1%) reported having schizophrenia or other psychosis, as diagnosed by a health professional; the weighted and adjusted estimate was 0.9% (0.7% to 1.0%). There was no statistical evidence that the prevalence estimates of schizophrenia and other psychosis varied by age, sex, or province of residence.
Conclusions: Additional studies incorporating a gold standard diagnostic interview should be carried out to determine the validity of the approach. However, responses to 2 self-report survey items provide what appears to be a plausible epidemiologic pattern.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/070674370605100407 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.
Mol Psychiatry
January 2025
Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
Schizophrenia is a chronic and severe mental disorder. It is currently treated with antipsychotic drugs (APD). However, APD's work only in a limited number of patients and may have cognition impairing side effects.
View Article and Find Full Text PDFEpigenetic Control in Schizophrenia.
Subcell Biochem
January 2025
Department of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy.
Schizophrenia is a severe and complex psychiatric condition ranking among the top 15 leading causes of disability worldwide. Despite the well-established heritability component, a complex interplay between genetic and environmental risk factors plays a key role in the development of schizophrenia and psychotic disorders in general. This chapter covers all the clinical evidence showing how the analysis of the epigenetic modulation in schizophrenia might be relevant to understand the pathogenesis of schizophrenia as well as potentially useful to develop new pharmacotherapies.
View Article and Find Full Text PDFImpact of Anticholinergic Burden on Cognitive Functions in Individuals with Bipolar Disorder, Schizoaffective Disorder, and Schizophrenia.
Clin Psychopharmacol Neurosci
February 2025
Department of Psychiatry, Pamukkale University, Denizli, Türkiye.
Objective: Bipolar disorder (BD), schizoaffective disorder (SAD), and schizophrenia (SCH) are psychiatric disorders characterized by persistent cognitive impairments, even during periods of remission. Psychotropic medications commonly used to manage these conditions have anticholinergic properties, which may contribute to cognitive impairment.
Methods: This study examined the relationship between anticholinergic medication burden and cognitive function in individuals diagnosed with BD, SAD, and SCH.
Xanomeline-trospium (Cobenfy) for Schizophrenia: A Review of the Literature.
Clin Psychopharmacol Neurosci
February 2025
Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.
Schizophrenia is a chronic and severe mental illness associated with substantial morbidity and mortality. Antipsychotics primarily rely on direct dopamine blockade, leading to potential life-interfering adverse events. The purpose of this review is to describe the safety and efficacy of xanomeline-trospium (Cobenfy), a Food and Drug Administration approved treatment for schizophrenia in adults.
View Article and Find Full Text PDFWhat is the current scope of research assessing patients' and clinicians' perspectives on clozapine treatment? A comprehensive scoping review.
BMJ Open
January 2025
Psychiatric Services Region Zealand East, Roskilde, Denmark.
Objectives: Clozapine is continuously underused. The existing systematic reviews addressing barriers to clozapine prescribing primarily focus on clinical staff's attitudes and perceived barriers to prescribing. However, a preliminary literature search revealed additional literature on the subject not previously included in systematic reviews, including literature on patient perspectives.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!